| 000 | 01745 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250516051406.0 | ||
| 264 | 0 | _c20120522 | |
| 008 | 201205s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdr344 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiller, K D | |
| 245 | 0 | 0 |
_aA phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cFeb 2012 |
||
| 300 |
_a331-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeart Diseases _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 | _aPilot Projects |
| 700 | 1 | _aO'Neill, A | |
| 700 | 1 | _aPerez, E A | |
| 700 | 1 | _aSeidman, A D | |
| 700 | 1 | _aSledge, G W | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 23 _gno. 2 _gp. 331-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdr344 _zAvailable from publisher's website |
| 999 |
_c21066441 _d21066441 |
||